The world's first food supplement with a unique formula containing a live beneficial virus
Biologically active
food supplement RIGVIR SE
- Intended for a weakened immune system
- For people with an increased risk of developing cancer
- Development is based on decades of scientific and clinical trials
- Intake only once a month
- Third party tested.
Rigvir SE – short description
Rigvir SE contains Vitamin B2, whey protein isolate and traces of a lyophilised non-genetically modified and non-pathogenic ECHO-7 virus Rigvir.
Rigvir SE ingredients are included in a capsule with special coating (hydroxypropyl methylcellulose) that allows it to cross the stomach and reach the intestine which is the most suitable environment for the ECHO-7 virus to provide its maximum benefit. The amount of ECHO-7 virus is multiple times smaller than the one used in the production of the Rigvir medicine.
Rigvir SE contains milk; does not contain gluten, wheat, yeast or soy.
It is important to observe temperature regimen in the storage and during transportation of Rigvir SE.
Rigvir SE active ingredient ECHO-7 virus is internationally patented.
Note. ECHO-7 virus Rigvir in the form of injectable medicine has been registered in 2004 and is still successfully used these days in the treatment of various cancer types and prevention of metastasis, as well as by people with increased cancer risks.
More information on:
- Rigvir virus producer’s web page – www.rigvir.com
- National Library of Medicine – www.pubmed.ncbi.nlm.nih.gov/?term=RIGVIR
- “The advent of oncolytic virotherapy in oncology: The Rigvir® story” – www.sciencedirect.com/science/article/pii/S0014299918305053
- Patient testimonials – www.youtube.com/user/CancerVirotherapy
Target audience
Rigvir SE is intended for people with a weakened immune system and with an increased risk of developing cancer: genetic predisposition, increased tumour markers, age above 65, precancerous diseases (mycoplasmosis and toxoplasmosis, human papillomavirus (HPV), chronic obstructive pulmonary disease (COPD), Helicobacter pylori infection, polyps, Crohn’s disease, ulcerative colitis, diabetes etc.).
Safety – our priority
Rigvir SE has completed the necessary tests, including safety, toxicology and sterility.
The ingredients have been separately tested for many years. ECHO-7 virus is specially adapted for various cancer cell recognition. It is non-pathogenic and non-genetically modified; its harmlessness has been proved in long-term clinical practice and pre-clinical trials even with a multiple times greater dose compared to the one in Rigvir SE, ensuring an excellent safety and tolerance profile.
Note. We have created a counterfeit surveillance system that allows us to identify possible Rigvir SE counterfeits quickly and easily.
Quality – third party tested
Rigvir SE quality is checked on several levels:
- during production;
- while it is on the market;
- during storage in partner warehouses to ensure the required storage and monitoring conditions.
Independent third-party laboratories perform regular random Rigvir SE sample selection for sterility and stability testing.
Intake – only once a month
One Rigvir SE capsule per month with one glass of water in the morning on an empty stomach. If needed, the dose may be increased based on recommendations from a healthcare professional.
According to healthcare professionals’ recommendations, Rigvir SE should be taken for at least 3 consecutive months, 3 capsules in total.
Note. Rigvir SE is not intended to diagnose, treat, cure, or prevent any disease.
Studies – since the 1960s
The development of Rigvir SE is based on science, medicine and long-term pre-clinical and clinical practice.
More information on:
The advent of oncolytic virotherapy in oncology: The Rigvir® story.
Rigvir SE has completed several studies, including the ones related to virus stability and use with multiple times smaller virus amount than found in the Rigvir medicine.
Production – responsible
Production of Rigvir SE is a biotechnologically complicated, yet environmentally friendly process – without harmful waste and emissions.
Rigvir SE is manufactured in the European Union in GMP facilities according to the best pharmacy practices.
Packaging – safe and appealing
Each package is marked with a special sticker that protects against unauthorized opening and the risks of counterfeiting – Learn more
Package size: 95x70x25 mm.
Package weight: 20 g.
Storage
Keep refrigerated at optimum +4°C (39.2°F).
Improper storage conditions will cause product degradation.
Transport at a temperature up to +25°C (77°F) for up to 5 days. The five-day transportation limit is valid only once. Delivery to pharmacies, clinics and distributors takes place in a special temperature regime to maintain the five-day transportation limit at +25°C (77°F).
Expiration date of Rigvir SE is 12 months.
Best before: please see packaging.
Stability tests of Rigvir SE have been performed with a temperature and expiration date margin.
Warning!
Food supplements should not be used as a substitute for a complete and balanced diet.
Keep out of reach and sight of children. Children and pregnant or breastfeeding women should not use this supplement. Do not use if the sachet material is punctured or missing.
Contraindications – individual intolerance to dietary supplement components.
Rigvir SE is not intended to diagnose, treat, cure, or prevent any disease.
Instagram spotlight
You are welcome to follow our latest news and information. Be a witness how Smart Nanovirus® changes the world.
